TY  - JOUR 
AU  - Casal Rubio, Joaquín
PY  - 2015
SN  - 1699-048
UR  - http://hdl.handle.net/20.500.11940/6172
LA  - eng
TI  - Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
DO  - 10.1007/s12094-014-1210-x.
VL  - 17
ER  -